Sales & Earnings Briefs
This article was originally published in The Tan Sheet
Executive Summary
Pharmacia: Luden's throat drop acquisition, Nicorette launch in Japan spurred an 18% increase in global consumer health sales to $177 mil. in Q3, firm says Oct. 23. U.S. consumer health sales fell 3% to $75 mil. Worldwide Nicorette revenue leaped 51% to $75 mil., while domestic sales dropped 11% to $18 mil. Pharmacia licenses U.S. marketing rights for Nicorette to GlaxoSmithKline. Global and domestic revenue for Rogaine plunged 21% and 26%, respectively, to $26 mil. and $21 mil. Consolidated sales rose 4% to $4.47 bil. and earnings were up 70% to $428 mil., including restructuring and merger-related costs. Without the charges, income increased 24% to $541 mil....
You may also be interested in...
Schering-Plough Afrin, Lotrimin GMP Shortcomings Cited In FDA-483 Report
Batch validations at a Schering-Plough manufacturing site in Puerto Rico uncovered several problems related to Afrin nasal spray and Lotrimin antifungal, FDA-483 inspection reports show.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands